Hollencrest Capital Management’s AstraZeneca AZN Stock Holding History

Hollencrest Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-300	Closed	-$46K	–	1179
2025 Q3	$46K	Hold	300	–	–	﹤0.01%	570
2025 Q2	$41.9K	Hold	300	–	–	﹤0.01%	546
2025 Q1	$44.1K	Sell	300 -46	-13%	-$6.66K	﹤0.01%	543
2024 Q4	$45.3K	Hold	346	–	–	﹤0.01%	549
2024 Q3	$53.9K	Buy	346 +96	+38%	+$15.5K	﹤0.01%	504
2024 Q2	$39K	Hold	250	–	–	﹤0.01%	558
2024 Q1	$33.9K	Hold	250	–	–	﹤0.01%	544
2023 Q4	$33.7K	Hold	250	–	–	﹤0.01%	544
2023 Q3	$33.9K	Hold	250	–	–	﹤0.01%	534
2023 Q2	$35.8K	Hold	250	–	–	﹤0.01%	545
2023 Q1	$34.7K	Hold	250	–	–	﹤0.01%	541
2022 Q4	$33.9K	Buy	+250	New	+$31.4K	﹤0.01%	524
2021 Q1	–	Sell	-3,250	Closed	-$325K	–	381
2020 Q4	$325K	Buy	+3,250	New	+$344K	0.03%	230

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hollencrest Capital Management's AZN Position: Q4 2025 in Review

Hollencrest Capital Management sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 300 shares — an estimated $46K sold.

Hollencrest Capital Management first reported a position in AZN in Q4 2020 and held it in 13 quarters. The position peaked at $325K in Q4 2020. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Hollencrest Capital Management reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Hollencrest Capital Management sold 300 AstraZeneca shares in Q4 2025, an estimated $46K.
Hollencrest Capital Management first reported a position in AstraZeneca in Q4 2020 and held it in 13 quarters.
Hollencrest Capital Management's AstraZeneca position peaked at $325K in Q4 2020.
1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Hollencrest Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.